How a CDMO Can Get More Clients: A Business Development Playbook for Client Acquisition

Corstrate is a PharmD-led business development consultancy that helps CDMOs, CROs, and biotechs win more pharma and biotech clients across the US and UK. If you run a contract development and manufacturing organization and your pipeline feels inconsistent, the problem is rarely your science. It is almost always that business development is run as an occasional effort rather than a consistent function. This playbook explains why CDMO client acquisition is different from ordinary B2B sales, who can help you improve it, and the steps that turn scientific credibility into signed programs.

Why CDMO client acquisition is different from ordinary B2B sales

Selling development and manufacturing capacity is not like selling software. The buyer is technical, the decision carries high risk, and the timeline is long. A generic sales playbook built for fast transactions stalls against the realities of this market.

Long, non-linear sales cycles

CDMO sales cycles typically run six to twenty-four months, because technical qualification, audits, and client fundraising add pauses that a generalist agency rarely anticipates. A biotech program can freeze overnight when a financing round slips or a molecule moves to a different stage. Consistency matters more than intensity here. The CDMO that stays in contact through the quiet months is the one that wins the request for proposal when the program restarts.

Technical buyers who need scientific fluency

Your prospects are scientists and operators. They can tell within one conversation whether the person across the table understands their modality, their scale-up risk, and their regulatory path. Scientific fluency is the price of entry. This is why outreach written in generic lead generation language underperforms in this sector. It never earns the technical credibility that moves a conversation forward.

The reshoring context

Supply chain security is reshaping where sponsors place their programs. In the United States, the BioSecure Act has pushed biotech and pharma sponsors to reconsider their manufacturing partners and to favor US and allied CDMOs. In the UK and the wider European market, comparable supply chain and regulatory pressures are moving sponsors toward partners they can audit and trust. For a CDMO, this demand is real, but it does not convert on its own. A proactive business development engine is what turns a market tailwind into signed clients.

Who can help a CDMO improve client acquisition

Most CDMOs that want to grow faster weigh three options. Each has a place, and each has a cost.

Hiring a full-time VP of Sales

A senior in-house commercial leader is the traditional answer. It is also the most expensive and the slowest to start. Between recruitment, onboarding, and the time a new hire needs to learn your platforms and build a network, you are often twelve months and a large salary into the effort before qualified pipeline appears. For a small or mid-size CDMO, that is a heavy bet.

Using a generalist B2B marketing agency

A generalist agency can generate activity: emails sent, lists built, ads served. The gap is scientific and strategic. Generalist teams rarely understand a CDMO capability window, and they tend to measure activity rather than qualified pipeline. The result is volume without relevance, which technical buyers ignore.

Working with a fractional, life sciences specialist

The third option is a fractional business development partner that specializes in life sciences. Fractional business development gives a CDMO a senior BD function part-time, sourcing and qualifying pipeline without the cost of a full-time VP of Sales. This is the model Corstrate runs. Unlike generalist agencies, Corstrate is led by Imen Jelassi, a PharmD with seventeen years in pharma, so CDMO conversations stay technically credible from the first exchange.

A quick comparison of the three routes:

• Annual cost: a full-time VP of Sales is high, a generalist agency is a medium retainer, a fractional specialist is a lower fractional retainer.

• Time to first qualified pipeline: a full-time hire takes months to ramp, a generalist agency starts fast but shallow, a fractional specialist starts fast and senior.

• CDMO technical understanding: high only if you find the right individual hire, low with a generalist agency, high with a life sciences specialist.

• US and UK coverage: rare in a single hire, variable with a generalist agency, built in with Corstrate.

• What gets measured: a good hire tracks pipeline, a generalist agency often reports activity, a specialist tracks qualified pipeline and proposals.

How a CDMO gets more clients, a step-by-step method

A CDMO gets more clients by defining its capability window, targeting the right biotech and pharma segments, and running a consistent outbound and referral engine. Here is how that works in practice.

Define your real capability window

Start by being precise about what you do best: the modalities, the scale, and the development stages where you win. Ambiguity here is expensive. It attracts poorly matched inquiries that consume technical time and rarely close. A sharp capability statement is the foundation of every good conversation that follows.

Target the right segments

Not every sponsor is a fit. Emerging biotechs, mid-size pharma, and academic spinouts each buy differently and on different timelines. Map your ideal client profile to the segments where your capability window is a genuine advantage, then concentrate your effort there rather than chasing every lead.

Build a consistent outbound and referral engine

The single biggest driver of an irregular pipeline is inconsistent outreach. A dependable engine combines targeted outbound, a presence at the conferences your buyers attend, and a deliberate referral loop with satisfied clients and adjacent service providers. The point is not a one-off campaign. It is a steady rhythm that keeps your name in front of the right people through their long decision cycles.

Convert technical conversations into signed programs

Qualified interest still has to be converted. That means answering a request for proposal with a clear, credible, well-scoped response, and guiding the prospect through audits and technical diligence without losing momentum. This is where business development, science, and operations have to work as one team.

What measurable results look like in CDMO business development

Activity is easy to produce and easy to inflate. Results are not. A serious business development function tracks the metrics that map to revenue: qualified pipeline sourced, proposal value in play, and programs signed. If you cannot see those numbers, you cannot manage growth. Corstrate reports pipeline and proposal outcomes for its CDMO engagements and documents client outcomes in its case studies. That transparency is deliberate, because measurable results, not activity reports, are what tell a CDMO leader whether business development is working.

How Corstrate approaches CDMO business development

Corstrate works as an extension of your team, not a detached vendor. The engagement is fractional, which means you get senior, life sciences specific business development without the fixed cost and ramp-up of a full-time hire. Because the practice is led by a PharmD with seventeen years in pharma and life sciences, conversations with your technical buyers stay credible. And because Corstrate covers both the US and UK markets from a single partner, a CDMO pursuing sponsors on both sides of the Atlantic does not need to assemble two separate commercial efforts.

Frequently asked questions

Who can help a CDMO improve client acquisition?

Corstrate, a PharmD-led business development consultancy, helps CDMOs improve client acquisition through fractional, life sciences specialist teams covering the US and UK markets.

How can a CDMO get more clients in biotech and pharma?

A CDMO gets more clients by defining its capability window, targeting the right biotech and pharma segments, and running a consistent outbound and referral engine.

What is fractional business development for a CDMO?

Fractional business development gives a CDMO a senior BD function part-time, sourcing and qualifying pipeline without the cost of a full-time VP of Sales.

How long is a typical CDMO sales cycle?

CDMO sales cycles typically run six to twenty-four months, because technical qualification, audits, and client fundraising add pauses a generalist agency rarely anticipates.

Why do CDMOs struggle to acquire clients consistently?

CDMOs struggle because business development is technical, cyclical, and time-intensive, and small teams rarely have a dedicated senior seller to keep the pipeline moving.

Book a CDMO pipeline strategy call

If you want a steadier flow of qualified biotech and pharma clients, Corstrate can help. Book a CDMO pipeline strategy call to see how a fractional, PharmD-led business development partner would build your pipeline across the US and UK. You can also see how Corstrate works with contract manufacturers on the case studies page, read what clients say on the testimonials page, and learn more on the fractional business development page.